Clinical Trial

TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated February 24, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this single- arm, open-lable, dose escalation + dose expansion study is to evalulate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-678 in Chronic Myelogenous Leukemia patients who had failure with or are intolerant to TKI treatments.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-06-21; most recent amendment 2025-02-20.
Status change: Recruiting → Active, Not Recruiting 2025-02-20
Trial Details
NCT Number NCT05434312
Lead Sponsor Shenzhen TargetRx Co., Ltd.
Collaborators: Peking University People's Hospital
Conditions Chronic Myelogenous Leukemia
Enrollment 90 participants
Start Date 2021-03-29
Primary Completion 2026-03 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2025-02-24